Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3303-3307

  Blonski, Katharina ^a   Schumacher, Udo ^a   Burkholder, Iris ^b   Edler, Lutz ^b   Nikbakht, Haleh ^a   Boeters, Ina ^a   Peters, Anja ^c   Kugler, Christian ^c   Horny, Hans Peter ^d   Langer, Martin ^e   Wilhelm Ogunbiyi, Karin ^e   Witthohn, Klaus ^e   Laack, Eckart ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c General Hospital Harburg   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e VISCUM AG   (Germany)

Author keywords

Adenocarcinoma of the lung; Aviscumine; Non small cell lung cancer; Prognostic factors; Recombinant mistletoe lectin

Indexed keywords

AVISCUMINE; LECTIN; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GLYCOSYLATION; HISTOCYTOCHEMISTRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLANT PREPARATIONS; PLANT PROTEINS; RECOMBINANT PROTEINS; TOXINS, BIOLOGICAL;

EID: 23344453861     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Barbieri L, Batelli MG and Stirpe F: Ribosome-inactivating proteins from plants. Biochim Biophys Acta 7754: 237-282, 1993.
2. Hajto T, Hostanska K and Gabius H-J: Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49: 4803-4808, 1989.
3. Hajto T, Hostanska K, Frei K, Rordorf C and Gabius H-J: Increased secretion of tumour necrosis factor alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to β galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50: 3322-3326, 1990.
4. Schumacher U, Schumacher D, Schwarz T and Pfüller U: Cell biological and immunopharmacological investigations on the use of mistletoe lectin I (ML-I). In: Phytopharmaka II Forschung und Klinische Anwendung. Loew D, Rietbrock N (eds.). Steinkopff Verlag Darmstadt, pp. 197-204, 1996.
5. Eck J, Langer M, Möckel B, Baur A, Rothe M, Zinke H and Lentzen HV: Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur J Biochem 264: 775-784, 1996.
6. Eck J, Langer M, Möckel B, Witthohn K, Zinke H and Lentzen H: Characterization of recombinant and plant derived mistletoe lectin and their B-chain. Eur J Biochem 265: 788-797, 1999.
7. Habeck M: Mistletoe compound enters clinical trials. Drug Discov Today 8: 52-53, 2003.
8. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351-360, 2004.
9. Clifton F and Mountain MD: Revisions in the international system for staging lung cancer. Chest 777: 1711-1717, 1997.
10. Bülzebruck H, Bopp R, Drings P et al: New aspects in the staging of lung cancer. Cancer 70: 1102-1110, 1992.
11. Laack E, Nikbarth H, Peters A, Kugler C, Jasiewicz Y, Edler L, Hossfeld DK and Schumacher U: Lectin histochemistry of resected adenocarcinoma of the lung: only Helix pomatia agglutinin (HPA) binding is an independent prognostic factor. Am J Pathol 160: 1001-1008, 2002.
12. Muthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H, Neumann U and Peter-Katalinic J: Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Acα2-6Galβ1-4GlcNac residues. Biochemistry 43: 2996-3007, 2004.
13. Valentiner U, Pfüller U, Baum C and Schumacher U: The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology 171: 187-199, 2002.
14. Schumacher U, Stamouli A, Adam E, Peddie M and Pfüller U: Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines. Glycoconjugate J 12: 250-257, 1995.
15. Thies A, Pfüller U, Schachner M, Horny H-P, Moll I and Schumacher U: Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy. Anticancer Res 21: 2883-2887, 2001.
16. Fukuda M: Cell surface carbohydrates: Cell type specific expression. In: Molecular Glycobiology. Fukuda M and Hindsgaul O (eds.). Oxford, IRL-Press, pp. 1-52, 1994.
17. Schumacher U, Mohamed M and Mitchell BS: Differential expression of carbohydrate residues in human breast and colon cancer cell lines grown in vitro and in vivo in SCID mice. Cancer 9: 247-254, 1996.
18. Moisenovich M, Tonevitsky A, Agapov I, Niwa H, Schewe H and Bereiter-Hahn J: Differences in endocytosis and intracellular sorting of ricin and viscumine in 3T3 cells. Eur J Cell Biol 81: 529-538, 2002.